Like so many others, Enzo Biochem (NYSE:ENZ) discloses that
its operations have been negatively impacted by COVID-19 disruptions,
including a material decline in laboratory testing volumes, adding that
the pandemic’s effects on its global supply chain could hamper
production within its life sciences unit as well as testing capabilities
in its clinical lab. It may also experience difficulties collecting
payments from customers.
COVID-19 products and services should partially offset revenue declines.
At the end of March, it had $48M in cash and no
long-term debt. Due to the high level of uncertainty related to the
duration and effects of the contagion, it is unable to estimate the
impact on its operations going forward.
https://seekingalpha.com/news/3559981-enzo-biochem-takes-hit-from-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.